Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

IRVINE, Calif., Aug. 27 /PRNewswire-FirstCall/ -- IDM Pharma (Nasdaq: IDMI) today announced that Jeffrey W. Sherman, M.D., F.A.C.P. has been appointed as the Company's Chief Medical Officer and Senior Vice President of Research and Development. Dr. Sherman will join the Company in September and will report to President and CEO Timothy P. Walbert.

Dr. Sherman brings close to 20 years of pharmaceutical experience to IDM Pharma and will lead the regulatory and clinical strategy for L-MTP-PE and the development of the Company's pipeline, including UVIDEM and IDM-2101. He joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he served as Vice President of Clinical Science and was focused on developing Takeda's oncology pipeline.

"Dr. Sherman's depth of oncology experience and pharmaceutical and biotechnology expertise will be an asset as we continue to work through the regulatory process with L-MTP-PE and develop our oncology pipeline," said Timothy P. Walbert, President and Chief Executive Officer of IDM Pharma, Inc. "In the near-term, Dr. Sherman will oversee the preparation and submission of the L-MTP-PE NDA amendment in the US and work closely with regulatory authorities in Europe to complete the L-MTP-PE review process."

About Dr. Jeffrey Sherman

Dr. Sherman joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he served as Vice President of Clinical Science, Oncology. Prior to Takeda, Dr. Sherman served as Chief Medical Officer and Executive Vice President at NeoPharm, Inc. where he was responsible for developing clinical drug research and development strategies.

Before joining NeoPharm, Dr. Sherman held various roles at Searle/Pharmacia Research and Development, and Medical Marketing, including Executive Director of Clinical Research and Head of Oncology Medical Operatio
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ... others achieve true cognitive enhancement. Now, he is sharing ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... high throughput research solutions, today announced that Lupin ... has received delivery of Freeslate’s CM Protégé ... screening. , Lupin, headquartered in Mumbai, India, ... affordable generic and branded formulations and Active Pharmaceutical ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine ... cells grown under simulated embryonic conditions, today announced ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... (CCM). , This agreement is an ... Suneva Medical, through which Suneva has exclusively licensed ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... together with two institutes from the National Institutes ... reliable tools for bringing safer, more effective treatments ... collaborating with the National Center for Advancing Translational ... to develop better and more clinically predictive tissue ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... nanotubes as the critical component of a robust terahertz ... and communication devices, sensors and non-invasive medical imaging systems ... systems. The polarizer developed by the Rice lab ... engineering and of physics and astronomy, is the most ...
... (OTCBB: SNGX) (Soligenix or the Company), a development stage ... Amendment to its Amended and Restated Certificate of Incorporation ... stock which will take effect tomorrow morning. ... an opportune time to effect a reverse stock split," ...
...  bioTheranostics, Inc., a bioMerieux company that develops innovative ... introduced a new product line of high medical ... called PRECIS Precision Medicine by bioTheranostics(SM). Precision medicine, ... diagnosis of primary tumor site and predictive biomarkers ...
Cached Biology Technology:Research at Rice University leads to nanotube-based device for communication, security, sensing 2Research at Rice University leads to nanotube-based device for communication, security, sensing 3Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 2Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 3Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 4bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 2bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 3
(Date:4/15/2014)... nanoparticle form could help reduce side effects by targeting ... scientists have developed nanoparticles that deliver one or two ... design particles that can carry any more than that ... devised a new way to build such nanoparticles, making ... drugs. In a paper published in the Journal ...
(Date:4/15/2014)... in the Congo Basin to increase by 0.7 ... greenhouse gases by half, according to a study ... , Explosive population growth and inefficient agricultural practices ... Central Africa. A team of researchers from the ... affect longer-term temperatures in the region. Using a ...
(Date:4/15/2014)... systems soon could be powering the forklifts used in ... with faster refueling times than ever before, courtesy of ... Carriers (HHC). , The goal of the project is ... refuel at low pressure four to five times faster ... hydrogen a competitive advantage over batteries for a big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Study: Deforestation could intensify climate change in Congo Basin by half 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4
... may have more in common than previously thought. At ... Bejan and Penn State biologist James Marden. What they ... systems from animal locomotion to the formation of river ... Flows evolve to reduce friction or other forms of resistance, ...
... dismaying reports that a promising antitumor drug could, in theory, ... Japanese team of researchers that suggests a potentially better option. ... Journal of Experimental Medicine (online April 27). ... new blood vessels that feed growing tumors. Agents that block ...
... Each year, the Entomological Society of America (ESA) features ... are a lively question-and-answer, college bowl-style competition on ... an important and entertaining component of the ESA Annual ... five regional Branches will compete in the national competition ...
Cached Biology News:Unifying the animate and the inanimate designs of nature 2A longer lasting tumor blocker 2Entomological Society of America's Linnaean Games teams selected 2
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... Roche Applied Science, which pioneered the blending ... High Fidelity and Expand Long Template PCR ... PCR System the first product of ... This new blend combines Taq DNA Polymerase ...
... 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat ... precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM ... 0.01% BSA, 50% glycerol. Shipping and Storage: Shipped ... One unit is defined as the amount of ...
Biology Products: